Navigation Links
AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Date:1/3/2008

results in an average survival time of 6.2 to 7.8 months in large multicenter studies. Two drugs are FDA-approved to treat metastatic melanoma: the alkylating agent dacarbazine, and the immunotherapy agent interleukin-2. Dacarbazine as a single agent has minimal activity and interleukin 2 is not widely used because of substantial toxicity. There have been no new treatments for metastatic melanoma approved by the FDA in over 10 years. In studies of dacarbazine as a single agent to treat malignant melanoma, median overall survival has ranged from 6-8 months.

About Amplimexon

Amplimexon is AmpliMed's parenteral formulation of imexon. Imexon is a cyanoaziridine compound which showed tantalizing evidence of activity in limited studies in lung cancer, melanoma and breast cancer that were documented in publications in the 1980s. The potential of imexon as a cancer drug was never fully explored, until 1994, when AmpliMed co-founding scientists Drs. Evan Hersh, David Alberts, Robert Dorr and William Remers initiated a program to decipher Amplimexon's novel mechanism of action. This led to the initiation in 2003 of a Phase I clinical study of the drug as a stand-alone therapy in late-stage cancer patients. Further preclinical research revealed that the combined use of Amplimexon and certain other chemotherapeutics resulted in a significant increase in efficacy compared to either drug alone. These findings are now being translated into a series of Phase I/II clinical studies of combination therapy in patients with various types of cancer.

About AmpliMed Corporation

AmpliMed Corporation was founded in 1989 with the support of the University of Arizona Technology Development Corporation and is focused on the clinical development of chemotherapeutic agents for cancer. AmpliMed's strategy is to develop anti-cancer drugs with novel mechanisms of action designed to overcome some of the limitations, such as myelosuppression (suppression of blood cell count
'/>"/>

SOURCE AmpliMed Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Immunosyn Corporation Releases SF-1019 Study Results
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
3. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
4. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
5. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
6. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
7. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
8. Alfacell Corporation to Present at UBS Global Life Sciences Conference
9. CEL-SCI Corporation Releases Letter to Shareholders
10. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
11. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... board of directors of Eli Lilly and Company (NYSE: ... the first quarter of 2010 of $0.49 a share ... is payable March 10, 2010 to shareholders of record ... 12, 2010. ,, Lilly, a leading innovation-driven corporation, is ... the latest research from its own worldwide laboratories and ...
(Date:12/14/2009)... Dec. 14 Zargis Medical Corp., a ... ) and a spin-off from Siemens Corporate Research ... it has begun selling its award-winning Zargis Cardioscan(TM) ... Cardioscan and its accompanying Bluetooth®-enabled electronic stethoscope were ... "2009 Innovation of the Year." Cardioscan ...
(Date:12/14/2009)... Gibraltar Associates, a leading public ... domestic communications and issues management, today announced ... PositiveID Corporation (Nasdaq: PSID ) to ... of record. Gibraltar Associates will conduct media ... the Company on its public relations programs. ...
Breaking Medicine Technology:Zargis Cardioscan 'The Intelligent Stethoscope' Now Available on Amazon.com 2Gibraltar Associates Named Agency of Record for Health Information and Diagnostic Provider PositiveID Corporation 2Philadelphia Born Ronald McDonald House 28R 29 Program Celebrates 35 Years 59433 1Philadelphia Born Ronald McDonald House 28R 29 Program Celebrates 35 Years 59433 2Philadelphia Born Ronald McDonald House 28R 29 Program Celebrates 35 Years 59433 3Bionovo Adds Dr Debu Tripathy to Their Medical Advisory Board 59431 1Bionovo Adds Dr Debu Tripathy to Their Medical Advisory Board 59431 2Bionovo Adds Dr Debu Tripathy to Their Medical Advisory Board 59431 3Dr Floyd Bloom Joins aTyr Pharmas Scientific Advisory Board 14466 1Dr Floyd Bloom Joins aTyr Pharmas Scientific Advisory Board 14466 2Dr Floyd Bloom Joins aTyr Pharmas Scientific Advisory Board 14466 3
(Date:12/14/2009)... bump in odds is small and shouldn,t worry most ... -- Older women who take antidepressants may have a ... death compared to women not on the medications, a ... different from clinical significance," stressed Dr. Jordan W. Smoller, ... and lead author of a report in the Dec. ...
(Date:12/14/2009)... 2 diabetes and obesity are linked to an increased ... that insulin glargine (a synthetic insulin preparation marketed under ... higher risk of certain cancers than other insulins or ... unable to control for important factors such as obesity ... the other hand, a large randomized trial designed to ...
(Date:12/14/2009)... functioning , , , MONDAY, Dec. 14 (HealthDay News) -- ... live longer than those who look older than their ... from research that involved 1,826 Danish twins, aged 70 ... and then had their faces photographed. Three groups of ... they perceived the participants to be. Twins were assessed ...
(Date:12/14/2009)... and the United Nations Foundation’s Nothing But Nets tipped off a ... HP--to send anti-malaria bed nets to refugees in 11 African countries. ... and runs through January 31, 2010. , ... ... National Basketball Association (NBA) and the United Nations Foundation’s Nothing But ...
(Date:12/14/2009)... Concetta F. Conkling of Moraga, CA, retired ... has been elected Chair of the Board of Trustees ... the nearly 90-year-old organization to which Helen Keller devoted ... York with offices in San Francisco, Dallas, ... is dedicated to expanding possibilities for people with vision ...
Breaking Medicine News(10 mins):Health News:Antidepressants May Raise Women's Stroke Risk 2Health News:Antidepressants May Raise Women's Stroke Risk 3Health News:UNC scientists coordinate study of link between insulin use and cancer in people with diabetes 2Health News:Looking Younger Than Your Age May Mean Longer Life 2Health News:NBA Cares and United Nations Foundation Partner to Launch Send A Net. Save A Life. See A Game. Presented By HP 2Health News:NBA Cares and United Nations Foundation Partner to Launch Send A Net. Save A Life. See A Game. Presented By HP 3Health News:NBA Cares and United Nations Foundation Partner to Launch Send A Net. Save A Life. See A Game. Presented By HP 4Health News:The American Foundation for the Blind Welcomes New Board Chair, Concetta F. Conkling 2
... Society of Cardiology (ESC) is calling for concerted action ... the World Heart Organisation (WHO). // ... full extent of the global burden of chronic diseases ... is anticipated that a global action to prevent chronic ...
... upon the foods we eat, the products we buy, the ... we spend time // . Evaluation of stimulus valence is ... uses it as a basic category for organizing information and ... to be immediate, unintentional and linked to behavioral responses. ...
... agreement in principle to enable the smooth transfer of ... is an encouraging sign for Indian bioscience. But slow ... India’s grandiose scheme to become the global hub of ... of becoming a major player. , ,Discussions in ...
... alarming rise in human cases of bird flu, causing increasing ... strong resolve in the scientific community to combat this impending ... flu has risen since October 5 when scientists from the ... reported finding similarities between the bird flu strain in Asia, ...
... dream come true for the scientists who been working hard ... expected to take an extra step ahead as it is ... as well as their offspring, are safe to eat., ... techniques, with Canadian Scientists having proved themselves following the success ...
... against, a London based leading drug company, GlaxoSmithKline for ... to the U.S. Food and Drug Administration two years ... review. This became evident last November when The FDA ... , ,The Public Citizen Group has registered a ...
Other Medicine News:Health News:Conditioning preferences in children 2Health News:Biologicals Transfer Proposal between US and Indian Biotechnology 2Health News:FDA Mislead On Asthma Drug By GlaxoSmithKline 2
... the new PRONEB® ULTRA compressor. This high ... while delivering more medication to the patient's ... PLUS® or PARI LC STAR® Reusable Nebulizer, ... for inhalation and retention into the lungs. ...
... Graham-Field has been developing diverse ... 58 years. Our medical-surgical products ... for innovation, quality and customer ... include the Labtron® line of ...
... TREK™ Compact Compressor is for active patients ... anywhere and everywhere. The compressor is small ... source optionsworldwide AC compatibility (100 to 240V), ... patients the freedom to take aerosol treatments ...
... ,Allied Healthcares Timeter® PCS 414 portable air compressor ... that you may wonder if its running. Youll ... a durable, mar-resistant steel case thats easy to ... 26.5 pounds. The PCS 414 has been engineered ...
Medicine Products: